Circulation. Cardiovascular interventions
-
Circ Cardiovasc Interv · Dec 2012
Randomized Controlled Trial Comparative StudyRandomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Ticagrelor and prasugrel provide stronger platelet inhibition compared with clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported in ST-segment-elevation myocardial infarction patients. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT01463163.
-
Circ Cardiovasc Interv · Dec 2012
Randomized Controlled Trial Multicenter StudyPaclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial.
Peripheral percutaneous transluminal angioplasty is fraught with a substantial risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating was compared with uncoated balloons in patients undergoing femoro-popliteal percutaneous transluminal angioplasty. ⋯ URL http://www.clinicaltrials.gov. Unique identifier: NCT01083030.
-
Circ Cardiovasc Interv · Dec 2012
Multicenter StudyPredictors of clinical outcomes in patients with severe aortic stenosis undergoing TAVI: a multistate analysis.
Patients with severe aortic stenosis at increased surgical risk continue to experience compromised long-term survival despite successful transcatheter aortic valve implantation. We used time-related pathways in a multistate analysis to identify predictors of adverse long-term outcome in patients who underwent transcatheter aortic valve implantation. ⋯ A body mass index ≤20 kg/m(2) was identified as a primary predictor of stroke and death after transcatheter aortic valve implantation during long-term follow-up, whereas transapical access emerged as a predictor of kidney injury and ABC. Age >80 years, body mass index ≤20 kg/m(2), prior stroke, and presence of atrial fibrillation at baseline increased the risk of stroke and death after an intercurrent event of ABC.
-
Circ Cardiovasc Interv · Dec 2012
Multicenter StudyPercutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension.
Chronic thromboembolic pulmonary hypertension leads to pulmonary hypertension and right-sided heart failure. The purpose of this study was to investigate the efficacy of percutaneous transluminal pulmonary angioplasty (PTPA) for the treatment of chronic thromboembolic pulmonary hypertension. ⋯ URL: http://www.umin.ac.jp. Unique identifier: UMIN000001572.
-
Circ Cardiovasc Interv · Dec 2012
Comparative StudyBivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Data from randomized trials has demonstrated the superiority of bivalirudin to glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous coronary intervention. Real-world performance of bivalirudin in primary percutaneous coronary intervention and the benefit of bivalirudin over heparin remain unknown in an era of routine dual antiplatelet therapy. ⋯ Bivalirudin use compared with glycoprotein IIb/IIIa inhibitors plus heparin as an antithrombotic strategy in primary percutaneous coronary intervention results in less major bleeding in contemporary practice. A benefit of bivalirudin over heparin could not be established with this registry and requires additional investigations to either confirm or refute.